Background-Exercise oscillatory ventilation (EOV) is a noninvasive parameter that potently predicts outcomes in systolic heart failure (HF). However, mechanistic insights into EOV have been limited by the absence of studies relating EOV to invasive hemodynamic measurements and blood gases performed during exercise. Methods and Results-Fifty-six patients with systolic HF (meanϮSEM age, 59Ϯ2 years; left ventricular ejection fraction, 30Ϯ1%) and 19 age-matched control subjects were studied with incremental cardiopulmonary exercise testing. Fick cardiac outputs, filling pressures, and arterial blood gases were measured at 1-minute intervals during exercise. We detected EOV in 45% of HF (HFϩEOV) patients and in none of the control subjects. The HFϩEOV group did not differ from the HF patients without EOV (HFϪEOV) in age, sex, body mass index, left ventricular ejection fraction, or origin of HF. Univariate predictors of the presence of EOV in HF, among measurements performed during exercise, included higher right atrial pressure and pulmonary capillary wedge pressure and lower cardiac index (CI) but not PaCO 2 or PaO 2 . Multivariate logistic regression identified that low exercise CI is the strongest predictor of EOV (odds ratio, 1.39 for each 1.0-L ⅐ min Ϫ1 ⅐ m Ϫ2 decrement in CI; 95% confidence interval, 1.14 -1.70; Pϭ0.001). Among HF patients with EOV, exercise CI was inversely related to EOV cycle length (RϭϪ0.71) and amplitude (RϭϪ0.60; both PϽ0.001). In 11 HFϩEOV subjects treated with 12 weeks of sildenafil, EOV cycle length and amplitude decreased proportionately to increases in CI. Conclusion-Exercise oscillatory ventilation is closely related to reduced CI and elevated filling pressures during exercise and may be an important surrogate for exercise-induced hemodynamic impairment in HF patients. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00309790.
P eriodic breathing (PB), the cyclic variation of ventilation with a period of Ϸ1 minute at rest, has been a recognized feature of systolic heart failure (HF) for almost 200 years. 1, 2 More recently, cyclic fluctuations in minute ventilation during exercise, called exercise oscillatory ventilation (EOV), have been observed in 19% to 51% of patients with HF. [3] [4] [5] [6] [7] [8] Exercise oscillatory ventilation has emerged as a potent independent risk factor for adverse prognosis in HF that is additive to traditional echocardiographic and metabolic indexes of clinical risk. 3, 5, [7] [8] [9] [10] 
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Despite the clear association between EOV and outcomes in chronic HF, data on the mechanistic basis for EOV are limited. Theoretical models to explain PB at rest implicate instability in the feedback systems controlling ventila-tion. [11] [12] [13] [14] [15] Ventilation is regulated through the feedback loop between pulmonary gas exchanging capillaries and chemoreceptors in the carotid bodies (peripheral) and the medulla (central) that respond to O 2 and CO 2 levels in blood. [11] [12] [13] [14] [15] [16] As with any feedback control system, instability and oscillations in ventilation in HF may arise from a delay in information transfer (ie, increased circulation time owing to reduced cardiac index), 8, 14 an increase in controller gain (ie, increased chemosensitivity), 16, 17 or reduction in system damping (ie, baroreflex impairment). 18 Increased chemosensitivity triggers a cycle of hyperventilation-induced reduction in PaCO 2 until the apnea threshold is approached and then hypoventilation until PaCO 2 rises and hyperventilation resumes. Overstimulation of the ventilatory control center by pulmonary congestion 19, 20 has also been postulated to contribute to PB at rest in HF.
Putative mechanisms involved in the cause of PB during exercise (ie, EOV) have been extrapolated largely from studies of PB at rest and during sleep. 8, 21, 22 Metabolic abnormalities in skeletal muscle caused by HF may also lead to enhanced ergoreflex during exercise, 23 increasing central chemosensitivity and EOV. In the 1 study that examined both PB during sleep and EOV in the same patients, however, only one third of patients with either PB at rest or EOV had both conditions. The lack of overlap between PB during exercise and during sleep in this study indicates potentially distinct pathophysiological mechanisms mediating PB at rest, during sleep, and during exertion. 3 To date, however, simultaneous measurements of ventilatory drive (ie, PaCO 2 ), systemic oxygenation (PaO 2 ), circulatory delay (ie, cardiac index [CI]), and pulmonary congestion (ie, pulmonary capillary wedge pressure [PCWP]) have not been performed during exercise and related to EOV.
In this study, we hypothesized that EOV is related primarily to an impaired ability to augment CI during exercise, with the resultant circulatory delay causing instability in the ventilatory control feedback loop. To test this hypothesis, we measured right heart hemodynamics, arterial blood gases, and ventilatory response patterns at rest and throughout exercise in patients with systolic HF and in matched control subjects. We associated amplitudes and cycle lengths of oscillations with ventilatory gas exchange parameters and exercise hemodynamic measurements in HF patients with EOV (HFϩEOV) and without EOV (HFϪEOV). Finally, we assessed whether previously demonstrated improvements in CI with administration of the phosphodiesterase-5 inhibitor sildenafil 24 would reduce oscillatory cycle length and amplitude in individuals who underwent cardiopulmonary exercise testing (CPET) before and after 12 weeks of treatment.
Methods

Patient Population and Study Design
Consecutive patients who underwent CPET with invasive hemodynamic monitoring at Massachusetts General Hospital, had left ventricular (LV) ejection fraction (LVEF) Ͻ0.40, and had chronic New York Heart Association class II to IV symptoms despite standard therapy were included in the study population. Exclusion criteria consisted of the following: incomplete pulmonary arterial catheter pressure measurements, documented intracardiac shunting, or the presence of a pulmonary mechanical limitation to exercise as defined by V E/(forced expiratory volume in 1 second [FEV 1 ]ϫ35) Ͼ0.7 at the anaerobic threshold. 25 Fifty-three percent of the LV dysfunction subjects (nϭ30) participated in a previously reported 12-week randomized, double-blind clinical trial of treatment with sildenafil (nϭ15) or placebo (nϭ15). 24 The control group was included to determine the extent to which hemodynamic and blood gas measurements in LV systolic dysfunction (LVSD) subjects with and without EOV differed from those of age-matched control subjects. Controls subjects were referred for CPET to evaluate dyspnea on exertion during the same period of time as the LVSD group. Control subjects were required to have normal LV function and normal exercise capacity as reflected by a peak V O 2 Ͼ80% of that predicted on the basis of age, sex, and height. Subjects meeting these inclusion criteria who were similar in age to the LVSD subjects composed the control cohort.
Cardiopulmonary Exercise Testing
All patients underwent placement of a pulmonary arterial catheter via the internal jugular vein and placement of a systemic arterial catheter via the radial artery. First-pass radionuclide ventriculography of both ventricles was performed immediately before cycle ergometry testing as previously described. 24 Subjects then underwent maximum incremental upright cycle ergometry CPET (5-to 15-W/min continuous ramp after an initial 3-minute period of unloaded exercise; MedGraphics, St. Paul, MN) with simultaneous hemodynamic monitoring (Witt Biomedical Inc, Melbourne, FL) as previously described. 24, 26 In subjects enrolled in the clinical trial of sildenafil treatment, 24 CPET was performed at baseline and after 12 weeks of treatment with sildenafil or placebo. Right atrial pressure, pulmonary arterial pressure (PAP), PCWP, and mean systemic arterial pressure were measured in the upright position, at end expiration, while patients were seated on the cycle, at rest, and at 1-minute intervals during exercise. Fick cardiac outputs were also determined at 1-minute intervals throughout exercise by measuring O 2 uptake (V O 2 ) and simultaneous radial arterial and pulmonary arterial O 2 content to calculate the arteriovenous O 2 difference, C(a-v)O 2 . Peak V O 2 was defined as the highest O 2 uptake, averaged over 30 seconds, during the last minute of symptom-limited exercise, as previously described. 26
Ventilatory Gas Exchange
To account for oscillations in gas exchange variables, we averaged breath-by-breath gas exchange variables over 1 minute for comparison with other variables collected each minute during exercise (ie, PCWP and blood gases). Ventilatory efficiency (V E/V CO 2 slope) was calculated by previously defined techniques 27 using breath-by-breath data. Subjects were considered to have EOV if they had Ն3 consecutive, regular oscillations in ventilation (V E) during exercise, with V E oscillation amplitude Ն25% of average V E, 28, 29 persisting for Ն60% of exercise duration. 30 Oscillatory cycle length was measured as the average time from nadir to nadir for each respective oscillation. Oscillatory amplitude was measured as the difference between the peak V E of the oscillation and the average of the V E of the 2 surrounding nadirs ( Figure 1 ), as previously described. 3
Statistical Methods
The STATA 10.0 software package (StataCorp LP, College Station, TX) was used for statistical analysis. For our primary hypothesis that exercise CI differed between LVSD patients with and without EOV, on the basis of exercise hemodynamic measurements from previous studies of patients with LVSD in our laboratory, 24, 27 we used a coefficient of variation of 0.24 for exercise CI. We anticipated a 40% incidence of EOV within our LVSD population on the basis of previous studies in similar populations. [3] [4] [5] [6] [7] [8] We therefore determined that a 56-subject study would give us 85% power to detect a clinically meaningful 20% difference in exercise CI between groups. The Wilk-Shapiro test was used to assess the normality of distribution of the data. All continuous, normally distributed measurements are presented as meanϮSEM. Categorical data are reported as percentages. Group baseline characteristics were compared by use of the Student t test, Pearson 2 test, or Fisher exact test as appropriate.
For clinical characteristics, comparisons between groups for continuous variables were performed with unpaired 2-sample t tests or the Wilcoxon signed-rank test. Pearson or Spearman correlation coefficients were calculated on the basis of whether the data were either normally or not normally distributed, respectively. Relationships between EOV and other rest and exercise clinical variables were assessed by univariate and multivariate logistic regression. One-way ANOVA was used to assess the effect of treatment on differences in the change in continuous variables measured at baseline and at 12 weeks of study drug treatment. The sildenafil trial was registered (http://www.clinicaltrials.gov; identifier, NCT00309790) and was approved by the Institutional Review Board; separate Institutional Review Board approval was obtained to study patients outside the sildenafil trial.
The authors had full access to and take full responsibility for the integrity of the data. All authors have agreed to the manuscript as written.
Results
Population Characteristics
Baseline characteristics for HF subjects (nϭ56), stratified according to the presence or absence of EOV, and control subjects (nϭ19) are reported in Table 1 . All patients surpassed their ventilatory anaerobic thresholds and lactate thresholds during exercise. Peak exercise capacity (V O 2 ) in the HF group as a whole (12.4Ϯ0.5 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was markedly less than that observed in age-matched control subjects (23.9Ϯ1.6 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ; PϽ0.001).
Exercise oscillatory ventilation was present in 45% of the HF patients (HFϩEOV) but in none of the control subjects. The HFϩEOV patients did not differ from the HF patients without EOV (HFϪEOV) in age, sex, body mass index, medication exposures, FEV 1 , or LVEF, but HFϩEOV patients did have lower right ventricular ejection fractions (RVEFs) than HFϪEOV patients (Table 1) . During exercise, HFϩEOV patients achieved lower peak V O 2 than HFϪEOV patients and had a trend toward higher V E/V CO 2 slopes (Table 1) .
Relationship Between Exercise Oscillatory Ventilation and Resting Hemodynamic Measurements
Resting hemodynamic measurements for all subjects are shown in Table 2 . Compared with control subjects, the HF group as a whole had elevated right atrial pressure, PAP, and PCWP. The HF subjects also had reduced resting CI and a compensatory increase in arteriovenous oxygen concentration [C(a-v)O 2 ] compared with control subjects.
Comparison of HFϩEOV and HFϪEOV groups indicated that the presence of EOV was associated with a greater degree of hemodynamic impairment than was its absence. Among HF patients, univariate predictors of the presence of EOV included higher PAP, higher PCWP, and lower CI (see Table  2 ; Table I in the online-only Data Supplement contains a complete list of univariate predictors of EOV). Resting CI was markedly less in HFϩEOV subjects (1.62Ϯ0.09 L ⅐ min Ϫ1 ⅐ Ϫ2 ) than in HFϪEOV subjects (2.03Ϯ0.08 L ⅐ min Ϫ1 ⅐ Ϫ2 ; Pϭ0.001).
In contrast, the resting PaCO 2 set point, which is indicative of respiratory drive, did not differ between the HFϩEOV and HFϪEOV groups (Table 1) . PaO 2 and pH also did not differ between the HFϩEOV and HFϪEOV groups ( Table 1) .
Relationship Between Exercise Oscillatory Ventilation and Physiological Parameters Measured During Exercise
Hemodynamic measurements derived during each minute of a standardized period of 6 minutes (for which all subjects were able to exercise) are displayed in Figure 2 . Hemodynamic measurements were averaged over the 6-minute period for comparison between groups. Control subjects demonstrated consistently lower exercise right atrial pressure, exercise PAP, and exercise PCWP and higher exercise CI and systemic blood pressures during exercise compared with both HFϩEOV and HFϪEOV patients ( Table 3) .
Among HF patients, exercise filling pressures were greater in the HFϩEOV group than in the HFϪEOV group, whereas the reverse was true for systolic blood pressure ( Table 3 ). The HFϩEOV patients had 25% lower exercise CI compared with the HFϪEOV patients (PϽ0.001). In parallel with the reduced ability to increase CI, HFϩEOV patients had significantly higher compensatory O 2 extraction (exercise C(av)O 2 ). There was a modest difference in exercise pH detected between the HFϩEOV and HFϪEOV groups (Table 3) . However, in contrast to the differences in hemodynamic values during exercise between the HFϩEOV and HFϪEOV groups, the 2 groups did not differ in V E, respiratory rate, PaO 2 , or PaCO 2 during exercise ( Figure 3 and Table 3 ).
When each of the univariate predictors of EOV ( Table I in the online-only Data Supplement) was combined into a multivariate analysis, only exercise CI was retained as a predictor of EOV (odds ratio, 1.39 for each 1.0-L ⅐ min Ϫ1 ⅐ m Ϫ2 decrement in CI; 95% confidence interval, 1.14 to 1.70; Pϭ0.001). Receiver-operating curve analysis was also performed to determine whether measurement of exercise CI was of incremental value to the measurement of resting CI for predicting EOV. For resting CI and exercise CI, the areas under the curve for predicting the presence of EOV were 0.65 and 0.79, respectively, with a significant increment in the C statistic (Pϭ0.02) with measurement of exercise CI ( Figure I in the online-only Data Supplement). Taken together, these findings indicate that EOV in HF is more closely related to impaired exercise hemodynamics than to indicators of ventilatory drive.
Amplitude and Duration of Oscillatory Ventilations
In HFϩEOV subjects, the average oscillatory amplitude was 7.5Ϯ0.7 L/min, with an average oscillatory cycle length of 67Ϯ5 seconds. The amplitude and duration of oscillations were inversely related to exercise CI (RϭϪ0.60 and RϭϪ0.71, respectively; both PՅ0.001; Figure 4 ). The HFϩEOV subjects with an EOV cycle length Ͻ1 minute had a significantly greater exercise CI than HFϩEOV subjects with an EOV cycle length Ͼ1 minute (2.6Ϯ0.2 versus 2.0Ϯ0.1 L ⅐ min Ϫ1 ⅐ m Ϫ2 ; Pϭ0.009). Exercise oscillatory ventilation amplitude and cycle length were also inversely related to RVEF (RϭϪ0.68 and RϭϪ0.48; both PϽ0.05; Figure 4 ). An EOV cycle length Ͼ1 minute was associated with an average RVEF of 29% compared with 41% in the HFϪEOV group (Pϭ0.003). The correlation between resting RVEF and CI at rest (Rϭ0.41; Pϭ0.051) was of borderline significance, but resting RVEF was correlated with exercise CI (Rϭ0.59; Pϭ0.003). In contrast, we did not observe a correlation between resting LVEF and CI either at rest (Rϭ0.08; Pϭ70) or with exercise (Rϭ0.11; Pϭ0.61). There was no association between oscillatory amplitude or duration with LVEF or with measures of gas exchange, including PaO 2 and PaCO 2 ( Figure 5 ).
In our study, those subjects in whom oscillations were clearly no longer present at peak exercise (nϭ9; see Figure II in the online-only Data Supplement) had higher peak CI (3.9Ϯ0.3 L ⅐ min Ϫ1 ⅐ m Ϫ2 ) than those in whom oscillations persisted throughout exercise (nϭ16; CIϭ3.0Ϯ0.1 L ⅐ min Ϫ1 ⅐ m Ϫ2 ; Pϭ0.036). Furthermore, patients in whom oscillations extinguished as they approached peak exercise demonstrated shorter EOV cycle length (55Ϯ4 versus 76Ϯ5 seconds; Pϭ0.006) and lower EOV amplitude (6.0Ϯ0.7 versus 8.9Ϯ0.9 L/min; Pϭ0.019) during the early standardized portion of exercise. 
Effect of Sildenafil on Exercise Oscillatory Ventilation Characteristics
Exercise oscillatory ventilation was present in 18 of the 30 patients included in a prior study of sildenafil for the treatment of secondary pulmonary hypertension in systolic HF. 24 Twelve weeks of sildenafil treatment reduced EOV cycle length (70Ϯ8 to 57Ϯ4 seconds) and oscillatory amplitude (7.8Ϯ1.3 to 6.3Ϯ1.4 L; PϽ0.05 by ANOVA with repeated measures for both comparisons) in the setting of increasing exercise CI by 18Ϯ6%, as previously reported. 24 Changes in oscillatory cycle length and amplitude after sildenafil treatment were inversely related to changes in exercise CI (RϭϪ0.72 and RϭϪ0.64, respectively; both PϽ0.01). The improvements in oscillatory cycle length and amplitude after treatment with sildenafil in 1 subject with particularly prominent oscillatory amplitudes and cycle lengths and another with more modest oscillatory ventilation are shown in Figure 6 . In both patients, oscillations appear to diminish during the final portion of exercise after sildenafil treatment.
Discussion
Exercise oscillatory ventilation is a noninvasive parameter that is easily measurable during submaximum exercise and purports a poor prognosis. We found that the presence of EOV signals hemodynamic impairment during exercise, as evidenced by increased right-and left-sided cardiac filling pressures and reduced systolic blood pressure and CI. Amplitude and cycle length of oscillations were also directly related to degree of impairment in exercise CI. A pharmaco- logical intervention that improved exercise CI in HF reduced the amplitude and cycle length of oscillations proportionately to increases in CI. These findings, along with the lack of relationship between the presence of EOV and PaCO 2 or PaO 2 during exercise, support the notion of a hemodynamic basis for EOV in HF. The prevalence of EOV in our cohort (45%) is higher than that reported in cohorts with less advanced HF (ie, 19% to 30%), 3,6 -8 but it is highly consistent with the prevalence of EOV reported by Sun and colleagues 5 (51%) in a cohort with exercise capacity similar to that of our HF subjects (peak V O 2 ϭ12 versus 12.6 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 in our cohort). Like other investigators, we found that EOV was not related to age, sex, or LVEF 7,29 but was associated with reduced peak V O 2 and a trend toward increased V E/V CO 2 slope. 5, 7, 8 Characterization of the relationship between hemodynamic measurements, blood gases, and EOV in HF patients has been limited by the technical challenges associated with hemodynamic and blood gas measurements during exercise and limited normative data on exercise hemodynamic values. 31 Our study is the first to relate EOV to serial measurements of circulatory delay (ie, CI), ventilatory drive (ie, PaCO 2 ), cardiac filling pressures (ie, PCWP), and systemic oxygenation (ie, PaO 2 ) during exercise.
Relationship Between Exercise Oscillatory Ventilation and Circulatory Delay
The role of prolonged circulation time in contributing to PB at rest has been debated for Ͼ50 years. 32, 33 Several studies characterizing PB have suggested a significant role of circulatory delay in PB generation 34, 35 ; others argue against this possibility. 36, 37 Proponents of the circulatory delay hypothesis for PB believe that time delay in transit of blood between lungs and chemoreceptors results in imprecise control of respiration, with undershooting and overshooting of the target ventilatory responses. 34 Agostoni et al 36 speculated that circulatory delay is unlikely to play a major role in determining EOV because EOV persists during incremental exercise with unchanged periodicity despite an expected exercise-induced increase in CI. However, none of the aforementioned studies directly measured CI during exercise. We found that patients with EOV do not augment CI normally; in fact, their CI during early exercise was only 2.2 L ⅐ min Ϫ1 ⅐ m Ϫ2 , markedly lower than that of the HFϪEOV patients (3.0 L ⅐ min Ϫ1 ⅐ m Ϫ2 ) and control subjects (4.2 L ⅐ min Ϫ1 ⅐ m Ϫ2 ). The near-maximum predicted oxygen extraction during early exercise in HFϩEOV further points to heightened reliance on oxygen extraction to increase V O 2 in the setting of inability to augment CI normally.
In multivariate analysis, mean exercise CI emerged as the leading predictor of the presence of EOV in our study. This observation extends findings from studies of PB at rest. Mortara et al 34 found that resting CI and prolonged lung-toear circulation time emerged as the major determinants of PB at rest. In addition, PB cycle length has been related to estimated lung-to-ear circulation time and lung-to-femoral artery circulation time by other investigators. 15, 38 However, EOV and its cycle length and amplitude have not previously been linked to resting or exercise CI or circulation time. Ribeiro and colleagues 39 observed that administration of milrinone abolished EOV in 3 HF patients and that heart transplantation reversed EOV in 2 additional patients. Although the Ribeiro et al findings support a central role of impaired hemodynamics in mediating EOV, exercise hemodynamics were not reported, and both phosphodiesterase inhibition and cardiac transplantation have multifactorial effects that could influence respiratory responses to exercise (ie, modulating chemosensitivity) 40, 41 beyond the hemodynamic effects of these interventions. Our finding that CI is the leading predictor of EOV in multivariate analysis extend the Ribeiro et al observations by linking EOV, as well as EOV cycle length and amplitude, directly to exercise CI.
The relatively constant cycle length of EOV within individuals, despite changes in CI during exercise, was evident in our study and in others. 36 This is intriguing because one would think that if EOV cycle length were closely related to exercise CI in HFϩEOV patients, then within individuals, EOV cycle length would decrease as CI increases. The modest rate of change in CI in our HFϩEOV patients may also explain why cycle length remains relatively constant. Furthermore, circulatory delay must be interpreted in the context of relative ventilatory drive and metabolic changes imposed by exercise. Therefore, inadequate CI at a given exercise intensity is likely to lead to persistent oscillatory ventilation during exercise.
A subset of patients in whom EOV extinguishes late in exercise have been reported to have better exercise capacity 29 and a more favorable prognosis than patients who continue to have oscillatory ventilation throughout exercise. 7 Although we focused on early, matched periods of exercise in this study, it is possible that late resolution of EOV during exercise may occur when CI increases above a certain threshold that shortens circulatory delay sufficiently to abolish EOV. Exercise oscillatory ventilation appears to resolve during late exercise after treatment with sildenafil with improvement in peak CI in the two subjects depicted in Figure 6 .
Relationship Between Cardiac Filling Pressures and Exercise Oscillatory Ventilation
We observed that right atrial pressure, PAP, and PCWP at rest and during exercise in HFϩEOV subjects were consistently greater than those observed in HFϪEOV subjects and control subjects ( Figure 2) . Elevated PCWP and pulmonary congestion stretches J receptors, which stimulate medullary respiratory centers via vagal afferents, leading to rapid shallow breathing, 42 hypocapnia, and initiation of PB at rest. 11, 19 Pulmonary congestion also reduces the ability of lungs to damp variations in O 2 and CO 2 concentrations through storage of gases, particularly CO 2 , in the residual capacity of the lungs. 14 Christie and Hayward 43 attributed PB at rest to pulmonary congestion because they were able to induce it by occluding a pulmonary vein. Olson et al 29 described increased left atrial volumes and increased echocardiographic estimates of resting filling pressures in HF subjects with EOV compared with matched HF control subjects without EOV. Our observation that right atrial pressure, PAP, and PCWP in HFϩEOV subjects remain higher than those in HFϪEOV subjects throughout exercise extends the findings of Christie and Hayward 43 and Olson et al. 29 Exercise oscillatory ventilation abates in some patients late in exercise, when PCWP would be expected to be increasing rather than decreasing, which has called the relationship between the presence of EOV and pulmonary congestion into question. 36 In multivariate analysis, CI, but not PCWP, emerged as the leading predictor of the presence of EOV.
Moreover, sildenafil treatment reduced EOV cycle length and amplitude in proportion to improvements in CI, whereas sildenafil did not alter PCWP during exercise in our HFϩEOV subjects treated with sildenafil. Together with the other findings, this suggests a dominant role of CI in determining the development of EOV. The interrelatedness of cardiac performance and filling pressures makes precise relative contributions of filling pressures and CI difficult to discern, but our concordant findings of reduced CI and elevated filling pressures relating to hemodynamic impairment to EOV suggest a central role of cardiac hemodynamic function in response to exercise in the genesis of EOV.
Relationship Between PaCO 2 , PaO 2 , and Exercise Oscillatory Ventilation
Arterial blood gases at rest and average values across the first 6 minutes of exercise revealed no relationship between rest or exercise PaCO 2 , PaO 2 , and EOV. This lack of association argues against a PaCO 2 set point close to the apnea threshold, serving as a major determinant of the presence of EOV. Although PaCO 2 fluctuates during EOV, with repeated sampling, one would expect to see lower cumulative PaCO 2 values if heightened ventilatory drive were present in EOV. However, minute ventilation and PaCO 2 at rest and during exercise did not differ in the HFϩEOV, HFϪEOV, and control groups. Moreover, the amplitude and duration of EOV were unrelated to mean PaCO 2 . Our findings that PaCO 2 did not differ in the HFϩEOV and HFϪEOV groups or in control subjects and that resting PaCO 2 values were within the normal range are consistent with findings by Agostoni et al, 36 who noted that patients with EOV had resting PaCO 2 of 39Ϯ3.8 mm Hg.
We did not directly measure central 44 or peripheral 45 chemosensitivity by systematically altering O 2 and CO 2 exposures and measuring V E responses. Therefore, we cannot rule out potential contributions of heightened chemosensitivity to EOV in our study. However, the similar levels of resting and exercise PaCO 2 , PaO 2 , and V E among HFϩEOV, HFϪEOV, and control subjects suggest that enhancement of chemosensitivity did not play a major role in mediating EOV in our study. Ergoreflex also was not assessed, but it too would be expected to increase V E during a matched period of exercise.
Clinical Implications
Exercise oscillatory ventilation is an easily recognized, reproducible, noninvasive measurement than can be measured during submaximal exercise testing and therefore represents an attractive surrogate for exercise hemodynamics. Exercise probes the reserve capacity of the cardiovascular system, but hemodynamic measurements during exercise are challenging to perform and are not routinely available during clinical CPET. By indicating an inadequate hemodynamic response to exercise (ie, impaired CI augmentation, increased filling pressures, and increased reliance on oxygen extraction) independently of LVEF, EOV may provide not only prognostic information but also an impetus to intensify therapy to optimize cardiac hemodynamics in HF subjects. The ability of a pharmacological intervention to alter EOV in our study also makes EOV a potential end point of interest for interventions expected to improve exercise hemodynamics and functional capacity in HF. Further work is needed to determine whether interventions such as cardiac resynchronization, intensification of neurohormonal blockade, diuretics, or emerging HF therapies will successfully attenuate EOV.
In addition to its implications in systolic HF, EOV has recently been recognized in patients with HF with preserved LVEF. The applicability of EOV as a potential indicator of cardiac compensation during exercise in HF with preserved LVEF is particularly intriguing because of the inherent challenges in discerning contributing factors to exercise intolerance in patients with HF with preserved LVEF.
Limitations
Our study has several limitations. Results were derived from a small patient cohort, and we tested multiple hypotheses regarding associations between EOV and physiological parameters, increasing the chance of type 1 error. Our control population was limited in size (nϭ19) because of the infrequency with which subjects without significant cardiopulmonary disease undergo CPET with invasive hemodynamic monitoring. However, our population was extensively phenotyped, and the consistency of our results pertaining to individual hemodynamic and gas exchange parameters lends credence to our findings. We applied strict definitions of EOV to separate patients into the HFϩEOV and HFϪEOV groups, which resulted in classifying HF subjects with lowlevel oscillations as nonoscillators. Optimal cut points for the definition of EOV have yet to be established. However, our findings correlating greater EOV cycle length and amplitude with worse cardiac function suggest that low amplitude and cycle length oscillations may be less clinically relevant. We used the gold standard Fick method to measure CI. Oscillations in V O 2 are known to occur, along with oscillations in V E, and therefore may result in variable values of derived CI. However, inclusion of 6 measurements per patient during exercise and the relatively linear increments in CI observed in our patients during exercise served to dampen potential variance introduced by oscillations in V O 2 .
Our findings should be viewed as exploratory until prospective trial data are available in which EOV is evaluated as a primary end point. We acknowledge that sildenafil may influence EOV through mechanisms beyond improving exercise CI. For example, theophylline, which acts as a nonselective phosphodiesterase inhibitor, has been shown to modulate chemosensitivity. It is possible that sildenafil worked through mechanisms other than improving CI. 40, 41 However, the close relationship between changes in EOV cycle length and amplitude and changes in CI with sildenafil treatment suggests that this intervention influenced EOV through improvements in CI.
Additional studies are needed to ascertain the reversibility of EOV with other HF therapeutic interventions. The lack of simultaneous echocardiographic assessment of mitral regurgitation at rest and during exercise precluded definitive assessment of the potential contribution of mitral regurgitation to EOV. Finally, our findings on the close relationship between exercise hemodynamics and EOV do not exclude the contribution of alternative mechanisms unrelated to hemodynamics such as increased neural respiratory drive.
Conclusions
In patients with systolic HF, the presence of EOV indicates significant impairment in resting and exercise cardiac performance, particularly when EOV cycle length exceeds 1 minute. Our findings support a central role of cardiac hemody-namics in the development of EOV and suggest that EOV may be a surrogate for exercise hemodynamics. The presence of EOV therefore could serve as a target for therapeutic interventions that are postulated to alter exercise hemodynamics and functional capacity.
